CANCER: Pemetrexed boosts non-small cell survival ratesPatients with nonsquamous cell carcinoma live up to 5.2 months longer, research shows CANCER: Second-line chemotherapy patients benefit from vandetanibDrop of 21% in risk of disease progression seen after 13-month followup Income gap in Ontario cancer screening Low rate of follow-up care to abnormal Pap tests Annual screening for skin cancer: Reasons for non-compliance Breast cancer testing to restart Ovary removal linked to higher risk of lung cancer Canadian researcher says result is preliminary, but intriguing Ovarian Cancer Helping patients navigate treatment courses and manage side effects CANCER: Anal cancer gold standard remains best approach Chemo should be standard approach for metastatic colorectal cancer 93% of patients had no future complications with chemo CANCER: Drug may reduce distant metastases in rectal cancer CANCER: New gene assay predicts colon cancer recurrence CANCER: North American chemo standard tops European standard for pancreatic cancer Gemcitabine offers fewer side-effects than 5-FU/FA, with same survival First Previous 68 69 70 71 Next Last
